Remove 2024 Remove Biopharma Remove Pharma Remove Prospecting
article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

article thumbnail

Defining Biotech Success in a Challenging Fundraising Environment

PM360

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This may best be achieved by large pharma companies, with their combined $200bn annual R&D budget, compared to smaller companies that are relying on external investment.

Biopharma 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HCP Engagement & Education

PM360

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

article thumbnail

Pharma is placing bigger bets on fewer, more strategic assets and platforms

Clarivate

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive.

Pharma 59
article thumbnail

What to watch in the life sciences in 2024

Clarivate

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111
article thumbnail

From viral vectors to nucleic acids: biopharma’s evolving manufacturing landscape

European Pharmaceutical Review

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? Sticking to the cell and gene therapy space, what’s your main prediction for 2024?

article thumbnail

The confluence of Biological and Data Science Revolutions Driving Innovations in Life Sciences, An MIT Sloan CDO Q&A with Mathai Mammen, CEO of Fogpharma

PM360

Given that you have led big pharma (J&J) and smaller firms (Theravance and now FogPharma), what are the career prospects and trajectory for mid-career / newly graduating students wanting to enter this vertical? v=M25xiFblCbE ) JPM 2024: FogPharma’s new CEO, Mathai Mammen, unveils ‘contrarian.’ www.youtube.com/watch?v=M25xiFblCbE